AORTARTIVION, INC.
- Market cap
- $1.14B
- as of 2026-10-23
- Latest close
- $23.30
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Medical Devices
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2023-11-29
Dashed line = amended filing (Form 4/A)
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Green Andrew MSVP, Regulatory and Quality | Sep 10 | Sep 11 | S | 11,480 | $24.97 | Sale −$286,656 | 40,160 | No | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Sep 3 | Sep 4 | S | 1,493 | $26.02 | Sale −$38,848 | 51,640 | No | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Sep 2 | Sep 4 | S | 6,510 | $27.27 | Sale −$177,528 | 53,133 | No | Form 4 |
| Mackin James PPresident & CEO | Aug 19 | Aug 20 | S | 70,000 | $28.96 | Sale −$2,027,200 | 877,275 | No | Form 4 |
| Berry Lance AEVP, COO, CFO & Treasurer | Aug 14 | Aug 17 | S | 715 | $28.55 | Sale −$20,413 | 210,112 | No | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Aug 14 | Aug 17 | S | 616 | $28.55 | Sale −$17,587 | 59,643 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 12 | Aug 12 | S | 977 | $28.49 | Sale −$27,835 | 184,118 | No | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Jun 11 | Jun 15 | M | 14,001 | $18.44 | $258,178 | 74,260 | Yes | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Jun 11 | Jun 15 | S | 14,001 | $20.71 | Sale −$289,961 | 60,259 | Yes | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Jun 11 | Jun 15 | M | 30,000 | $11.03 | $330,900 | 90,259 | Yes | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Jun 11 | Jun 15 | S | 30,000 | $20.69 | Sale −$620,700 | 60,259 | Yes | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Jun 11 | Jun 15 | M · derivative | 14,001 | $18.44 | $258,178 | not reported | Yes | Form 4 |
| Green Andrew MSVP, Regulatory and Quality | Jun 11 | Jun 15 | M · derivative | 30,000 | $11.03 | $330,900 | not reported | Yes | Form 4 |
| Semedo Anthony B. | Jun 2 | Jun 4 | J | 6,325 | $0.00 | $0 | 40,635 | No | Form 4 |
| Semedo Anthony B. | Jun 2 | Jun 4 | J | 6,325 | $0.00 | $0 | 6,325 | No | Form 4 |
| Ackerman Thomas F | May 18 | May 20 | A | 7,576 | $0.00 | $0 | 157,472 | No | Form 4 |
| Bevevino Daniel J | May 18 | May 20 | A | 7,576 | $0.00 | $0 | 157,637 | No | Form 4 |
| Bullock James | May 18 | May 20 | A | 7,576 | $0.00 | $0 | 76,223 | No | Form 4 |
| Burbank Jeffrey H | May 18 | May 20 | A | 7,576 | $0.00 | $0 | 61,372 | No | Form 4 |
| Hoff Elizabeth A | May 18 | May 20 | A | 7,576 | $0.00 | $0 | 34,765 | No | Form 4 |
| Salveson Jon W | May 18 | May 20 | A | 7,576 | $0.00 | $0 | 137,416 | No | Form 4 |
| Semedo Anthony B. | May 18 | May 20 | A | 7,576 | $0.00 | $0 | 46,960 | No | Form 4 |
| Borgstrom Marna P | May 18 | May 204/A | A | 7,576 | $0.00 | $0 | 56,664 | No | Form 4/A |
| Borgstrom Marna P | May 14 | May 19 | A | 7,850 | $0.00 | $0 | 56,938 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 4 | Mar 4 | S | 8,962 | $38.00 | Sale −$340,556 | 185,095 | No | Form 4 |
| Mackin James PPresident & CEO | Mar 3 | Mar 4 | S | 17,887 | $37.78 | Sale −$675,771 | 947,275 | No | Form 4 |
| Berry Lance AEVP, COO, CFO & Treasurer | Mar 3 | Mar 4 | S | 6,316 | $37.78 | Sale −$238,618 | 210,827 | No | Form 4 |
| Davis John EChief Commercial Officer | Mar 3 | Mar 4 | S | 4,573 | $37.78 | Sale −$172,768 | 230,794 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 3 | Mar 4 | S | 2,149 | $37.78 | Sale −$81,189 | 60,097 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 3 | Mar 4 | S | 3,843 | $37.78 | Sale −$145,189 | 194,057 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Mar 3 | Mar 4 | S | 901 | $37.78 | Sale −$34,040 | 139,088 | No | Form 4 |
| Mackin James PPresident & CEO | Mar 2 | Mar 4 | A | 116,948 | $0.00 | $0 | 965,162 | No | Form 4 |
| Berry Lance AEVP, COO, CFO & Treasurer | Mar 2 | Mar 4 | A | 40,874 | $0.00 | $0 | 217,143 | No | Form 4 |
| Davis John EChief Commercial Officer | Mar 2 | Mar 4 | A | 28,845 | $0.00 | $0 | 235,367 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 2 | Mar 4 | A | 21,838 | $0.00 | $0 | 62,246 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 2 | Mar 4 | A | 27,795 | $0.00 | $0 | 197,900 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Mar 2 | Mar 4 | A | 7,475 | $0.00 | $0 | 139,989 | No | Form 4 |
| Davis John EChief Commercial Officer | Mar 2 | Mar 3 | S | 2,784 | $38.02 | Sale −$105,848 | 206,522 | No | Form 4 |
| Berry Lance AEVP, COO, CFO & Treasurer | Mar 2 | Mar 3 | S | 5,178 | $38.02 | Sale −$196,868 | 176,269 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 2 | Mar 3 | S | 2,183 | $38.02 | Sale −$82,998 | 170,105 | No | Form 4 |
| Mackin James PPresident & CEO | Mar 2 | Mar 3 | S | 14,911 | $38.02 | Sale −$566,916 | 848,214 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 2 | Mar 3 | S | 1,513 | $38.02 | Sale −$57,524 | 40,408 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Mar 2 | Mar 3 | S | 641 | $38.02 | Sale −$24,371 | 132,514 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 24 | Feb 25 | S | 2,075 | $35.69 | Sale −$74,057 | 188,868 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 24 | Feb 25 | A | 20,438 | $0.00 | $0 | 209,306 | No | Form 4 |
| Berry Lance AEVP, COO, CFO & Treasurer | Feb 24 | Feb 25 | S | 4,485 | $35.69 | Sale −$160,070 | 143,965 | No | Form 4 |
| Berry Lance AEVP, COO, CFO & Treasurer | Feb 24 | Feb 25 | A | 37,482 | $0.00 | $0 | 181,447 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 24 | Feb 25 | S | 13,936 | $35.69 | Sale −$497,376 | 766,095 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 24 | Feb 25 | A | 97,030 | $0.00 | $0 | 863,125 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 24 | Feb 25 | S | 1,668 | $35.69 | Sale −$59,531 | 152,203 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 24 | Feb 25 | A | 20,085 | $0.00 | $0 | 172,288 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 24 | Feb 25 | S | 1,259 | $35.69 | Sale −$44,934 | 41,921 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 24 | Feb 25 | S | 830 | $35.69 | Sale −$29,623 | 127,497 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 24 | Feb 25 | A | 5,658 | $0.00 | $0 | 133,155 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 23 | Feb 25 | S | 3,773 | $37.59 | Sale −$141,827 | 190,943 | No | Form 4 |
| Berry Lance AEVP, COO, CFO & Treasurer | Feb 23 | Feb 25 | S | 4,981 | $37.59 | Sale −$187,236 | 148,450 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 23 | Feb 25 | S | 20,962 | $37.59 | Sale −$787,962 | 780,031 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 23 | Feb 25 | S | 3,079 | $37.59 | Sale −$115,740 | 153,871 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 23 | Feb 25 | S | 2,423 | $37.59 | Sale −$91,081 | 43,180 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 23 | Feb 25 | S | 1,731 | $37.59 | Sale −$65,068 | 128,327 | No | Form 4 |
| Davis John EChief Commercial Officer | Dec 15, 2025 | Dec 17, 2025 | S | 5,000 | $45.11 | Sale −$225,550 | 193,842 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 8, 2025 | Dec 9, 2025 | S | 4,572 | $44.42 | Sale −$203,088 | 130,058 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Dec 3, 2025 | Dec 4, 2025 | S | 2,048 | $45.30 | Sale −$92,774 | 161,360 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Dec 3, 2025 | Dec 4, 2025 | S | 5,267 | $45.30 | Sale −$238,595 | 156,093 | No | Form 4 |
| Mackin James PPresident & CEO | Dec 3, 2025 | Dec 4, 2025 | M | 30,921 | $29.62 | $915,880 | 831,914 | Yes | Form 4 |
| Mackin James PPresident & CEO | Dec 3, 2025 | Dec 4, 2025 | S | 30,921 | $45.46 | Sale −$1,405,669 | 800,993 | Yes | Form 4 |
| Mackin James PPresident & CEO | Dec 3, 2025 | Dec 4, 2025 | M · derivative | 30,921 | $29.62 | $915,880 | not reported | Yes | Form 4 |
| Mackin James PPresident & CEO | Dec 2, 2025 | Dec 3, 2025 | M | 30,921 | $29.62 | $915,880 | 831,914 | Yes | Form 4 |
| Mackin James PPresident & CEO | Dec 2, 2025 | Dec 3, 2025 | S | 30,921 | $45.56 | Sale −$1,408,761 | 800,993 | Yes | Form 4 |
| Mackin James PPresident & CEO | Dec 2, 2025 | Dec 3, 2025 | M · derivative | 30,921 | $29.62 | $915,880 | not reported | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 1, 2025 | Dec 2, 2025 | G | 750 | $0.00 | $0 | 134,630 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | M | 20,301 | $18.44 | $374,350 | 65,054 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | S | 14,586 | $44.92 | Sale −$655,203 | 50,468 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | S | 5,715 | $45.35 | Sale −$259,175 | 44,753 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | M | 27,075 | $11.03 | $298,637 | 71,828 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | S | 18,705 | $44.91 | Sale −$840,042 | 53,123 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | S | 8,370 | $45.35 | Sale −$379,580 | 44,753 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | M · derivative | 20,301 | $18.44 | $374,350 | not reported | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 21, 2025 | Nov 24, 2025 | M · derivative | 27,075 | $11.03 | $298,637 | not reported | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 20, 2025 | Nov 24, 2025 | S | 11,888 | $44.14 | Sale −$524,736 | 44,753 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 20, 2025 | Nov 24, 2025 | M | 2,033 | $18.44 | $37,489 | 46,786 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 20, 2025 | Nov 24, 2025 | S | 2,033 | $44.32 | Sale −$90,103 | 44,753 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 20, 2025 | Nov 24, 2025 | M | 1,355 | $11.03 | $14,946 | 46,108 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 20, 2025 | Nov 24, 2025 | S | 1,355 | $44.28 | Sale −$59,999 | 44,753 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 20, 2025 | Nov 24, 2025 | M · derivative | 2,033 | $18.44 | $37,489 | 20,301 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 20, 2025 | Nov 24, 2025 | M · derivative | 1,355 | $11.03 | $14,946 | 27,075 | No | Form 4 |
| Hoff Elizabeth A | Nov 18, 2025 | Nov 19, 2025 | S | 4,200 | $45.10 | Sale −$189,420 | 27,189 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Nov 17, 2025 | Nov 18, 2025 | S | 6,000 | $45.73 | Sale −$274,380 | 135,380 | No | Form 4 |
| Davis John EChief Commercial Officer | Nov 17, 2025 | Nov 18, 2025 | M | 6,394 | $29.62 | $189,390 | 205,236 | Yes | Form 4 |
| Davis John EChief Commercial Officer | Nov 17, 2025 | Nov 18, 2025 | S | 6,394 | $45.17 | Sale −$288,817 | 198,842 | Yes | Form 4 |
| Davis John EChief Commercial Officer | Nov 17, 2025 | Nov 18, 2025 | M · derivative | 6,394 | $29.62 | $189,390 | not reported | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 17, 2025 | Nov 18, 2025 | M | 6,394 | $29.62 | $189,390 | 169,802 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 17, 2025 | Nov 18, 2025 | S | 6,394 | $45.17 | Sale −$288,817 | 163,408 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 17, 2025 | Nov 18, 2025 | M · derivative | 6,394 | $29.62 | $189,390 | not reported | Yes | Form 4 |
| Davis John EChief Commercial Officer | Nov 14, 2025 | Nov 18, 2025 | M | 6,393 | $29.62 | $189,361 | 205,235 | Yes | Form 4 |
| Davis John EChief Commercial Officer | Nov 14, 2025 | Nov 18, 2025 | S | 6,393 | $44.67 | Sale −$285,575 | 198,842 | Yes | Form 4 |
| Davis John EChief Commercial Officer | Nov 14, 2025 | Nov 18, 2025 | M · derivative | 6,393 | $29.62 | $189,361 | not reported | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 14, 2025 | Nov 18, 2025 | M | 6,393 | $29.62 | $189,361 | 169,801 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 14, 2025 | Nov 18, 2025 | S | 6,393 | $45.00 | Sale −$287,685 | 163,408 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 14, 2025 | Nov 18, 2025 | M · derivative | 6,393 | $29.62 | $189,361 | not reported | Yes | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 13, 2025 | Nov 14, 2025 | S | 4,993 | $45.86 | Sale −$228,979 | 56,641 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 13, 2025 | Nov 14, 2025 | S | 5,761 | $45.86 | Sale −$264,199 | 163,408 | No | Form 4 |
| Mackin James PPresident & CEO | Nov 13, 2025 | Nov 14, 2025 | S | 34,210 | $45.86 | Sale −$1,568,871 | 800,993 | No | Form 4 |
| Davis John EChief Commercial Officer | Nov 13, 2025 | Nov 14, 2025 | S | 6,563 | $45.86 | Sale −$300,979 | 198,842 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Nov 13, 2025 | Nov 14, 2025 | S | 3,482 | $45.86 | Sale −$159,685 | 141,380 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 11, 2025 | Nov 12, 2025 | M | 10,000 | $11.03 | $110,300 | 179,169 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 11, 2025 | Nov 12, 2025 | S | 10,000 | $46.18 | Sale −$461,800 | 169,169 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 11, 2025 | Nov 12, 2025 | M · derivative | 10,000 | $11.03 | $110,300 | not reported | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Nov 10, 2025 | Nov 12, 2025 | S | 2,566 | $44.62 | Sale −$114,495 | 61,634 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Nov 10, 2025 | Nov 12, 2025 | S | 1,789 | $44.62 | Sale −$79,825 | 144,862 | No | Form 4 |
| Davis John EChief Commercial Officer | Nov 10, 2025 | Nov 12, 2025 | S | 3,373 | $44.62 | Sale −$150,503 | 205,405 | No | Form 4 |
| Mackin James PPresident & CEO | Nov 10, 2025 | Nov 12, 2025 | S | 17,580 | $44.62 | Sale −$784,420 | 835,203 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Nov 10, 2025 | Nov 12, 2025 | S | 2,960 | $44.62 | Sale −$132,075 | 169,169 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Aug 27, 2025 | Aug 28, 2025 | M | 18,200 | $11.03 | $200,746 | 82,400 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Aug 27, 2025 | Aug 28, 2025 | S | 18,200 | $44.02 | Sale −$801,164 | 64,200 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Aug 27, 2025 | Aug 28, 2025 | M · derivative | 18,200 | $11.03 | $200,746 | not reported | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 25, 2025 | Aug 26, 2025 | M | 10,000 | $11.03 | $110,300 | 182,129 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 25, 2025 | Aug 26, 2025 | S | 10,000 | $44.37 | Sale −$443,700 | 172,129 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 25, 2025 | Aug 26, 2025 | M · derivative | 10,000 | $11.03 | $110,300 | not reported | No | Form 4 |
| Mackin James PPresident & CEO | Aug 15, 2025 | Aug 19, 2025 | S | 12,500 | $42.32 | Sale −$529,000 | 852,783 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 12, 2025 | Aug 14, 2025 | M | 16,975 | $26.24 | $445,424 | 195,485 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 12, 2025 | Aug 14, 2025 | S | 16,975 | $43.01 | Sale −$730,095 | 178,510 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 12, 2025 | Aug 14, 2025 | S | 6,381 | $43.02 | Sale −$274,511 | 172,129 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 12, 2025 | Aug 14, 2025 | M · derivative | 16,975 | $26.24 | $445,424 | not reported | No | Form 4 |
| Davis John EChief Commercial Officer | Aug 12, 2025 | Aug 14, 2025 | M | 10,802 | $26.24 | $283,444 | 219,580 | No | Form 4 |
| Davis John EChief Commercial Officer | Aug 12, 2025 | Aug 14, 2025 | S | 10,802 | $43.67 | Sale −$471,723 | 208,778 | No | Form 4 |
| Davis John EChief Commercial Officer | Aug 12, 2025 | Aug 14, 2025 | M · derivative | 10,802 | $26.24 | $283,444 | not reported | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Aug 8, 2025 | Aug 11, 2025 | M | 7,992 | $29.62 | $236,723 | 154,643 | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Aug 8, 2025 | Aug 11, 2025 | S | 7,992 | $38.49 | Sale −$307,612 | 146,651 | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Aug 8, 2025 | Aug 11, 2025 | M · derivative | 7,992 | $29.62 | $236,723 | not reported | Yes | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Jun 17, 2025 | Jun 18, 2025 | S | 13,764 | $29.50 | Sale −$406,038 | 65,436 | Yes | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Jun 17, 2025 | Jun 18, 2025 | S | 1,236 | $29.50 | Sale −$36,462 | 64,200 | Yes | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Jun 13, 2025 | Jun 16, 2025 | S | 8,747 | $28.46 | Sale −$248,940 | 96,585 | Yes | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Jun 13, 2025 | Jun 16, 2025 | S | 1,253 | $28.47 | Sale −$35,673 | 95,332 | Yes | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Jun 13, 2025 | Jun 16, 2025 | S | 14,306 | $28.42 | Sale −$406,577 | 81,026 | Yes | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Jun 13, 2025 | Jun 16, 2025 | S | 1,826 | $28.43 | Sale −$51,913 | 79,200 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | May 27, 2025 | May 27, 2025 | S | 8,748 | $29.00 | Sale −$253,692 | 178,510 | No | Form 4 |
| Semedo Anthony B. | May 23, 2025 | May 27, 20254/A | S | 2,600 | $28.47 | Sale −$74,022 | 39,384 | No | Form 4/A |
| Bullock James | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 68,647 | No | Form 4 |
| Burbank Jeffrey H | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 53,796 | No | Form 4 |
| Hoff Elizabeth A | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 31,389 | No | Form 4 |
| Salveson Jon W | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 129,840 | No | Form 4 |
| Ackerman Thomas F | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 149,896 | No | Form 4 |
| Bevevino Daniel J | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 150,061 | No | Form 4 |
| Borgstrom Marna P | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 49,088 | No | Form 4 |
| Semedo Anthony B. | May 22, 2025 | May 27, 2025 | A | 6,325 | $0.00 | $0 | 41,984 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | May 21, 2025 | May 21, 2025 | S | 9,926 | $29.00 | Sale −$287,854 | 187,258 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | May 9, 2025 | May 12, 2025 | S | 5,737 | $29.13 | Sale −$167,119 | 110,143 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | May 9, 2025 | May 12, 2025 | S | 4,811 | $29.13 | Sale −$140,144 | 105,332 | No | Form 4 |
| Davis John EChief Commercial Officer | Mar 11, 2025 | Mar 12, 2025 | M | 15,910 | $21.55 | $342,861 | 223,878 | Yes | Form 4 |
| Davis John EChief Commercial Officer | Mar 11, 2025 | Mar 12, 2025 | S | 15,100 | $23.61 | Sale −$356,511 | 208,778 | Yes | Form 4 |
| Davis John EChief Commercial Officer | Mar 11, 2025 | Mar 12, 2025 | M · derivative | 15,910 | $21.55 | $342,861 | not reported | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 11, 2025 | Mar 12, 2025 | M | 19,092 | $21.55 | $411,433 | 215,204 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 11, 2025 | Mar 12, 2025 | S | 18,020 | $23.61 | Sale −$425,452 | 197,184 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 11, 2025 | Mar 12, 2025 | M · derivative | 19,092 | $21.55 | $411,433 | not reported | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 6, 2025 | Mar 10, 2025 | A | 25,493 | $0.00 | $0 | 198,236 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 6, 2025 | Mar 10, 2025 | S | 2,124 | $24.80 | Sale −$52,675 | 196,112 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 6, 2025 | Mar 10, 2025 | A | 19,240 | $0.00 | $0 | 117,483 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 6, 2025 | Mar 10, 2025 | S | 1,603 | $24.80 | Sale −$39,754 | 115,880 | No | Form 4 |
| Davis John EChief Commercial Officer | Mar 6, 2025 | Mar 10, 2025 | A | 25,654 | $0.00 | $0 | 210,586 | No | Form 4 |
| Davis John EChief Commercial Officer | Mar 6, 2025 | Mar 10, 2025 | S | 2,618 | $24.80 | Sale −$64,926 | 207,968 | No | Form 4 |
| Berry Lance AExecutive VP, CFO | Mar 6, 2025 | Mar 10, 2025 | A | 48,100 | $0.00 | $0 | 158,340 | No | Form 4 |
| Berry Lance AExecutive VP, CFO | Mar 6, 2025 | Mar 10, 2025 | S | 4,909 | $24.80 | Sale −$121,743 | 153,431 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Mar 6, 2025 | Mar 10, 2025 | A | 10,261 | $0.00 | $0 | 147,699 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Mar 6, 2025 | Mar 10, 2025 | S | 1,048 | $24.80 | Sale −$25,990 | 146,651 | No | Form 4 |
| Mackin James PPresident & CEO | Mar 6, 2025 | Mar 10, 2025 | A | 115,701 | $0.00 | $0 | 878,107 | Yes | Form 4 |
| Mackin James PPresident & CEO | Mar 6, 2025 | Mar 10, 2025 | S | 17,739 | $24.80 | Sale −$439,927 | 860,368 | Yes | Form 4 |
| Mackin James PPresident & CEO | Mar 6, 2025 | Mar 10, 2025 | M | 75,615 | $21.55 | $1,629,503 | 935,983 | Yes | Form 4 |
| Mackin James PPresident & CEO | Mar 6, 2025 | Mar 10, 2025 | S | 70,700 | $24.76 | Sale −$1,750,532 | 865,283 | Yes | Form 4 |
| Mackin James PPresident & CEO | Mar 6, 2025 | Mar 10, 2025 | M · derivative | 75,615 | $21.55 | $1,629,503 | not reported | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Mar 5, 2025 | Mar 6, 2025 | S | 472 | $25.29 | Sale −$11,937 | 172,743 | No | Form 4 |
| Semedo Anthony B. | Mar 5, 2025 | Mar 5, 2025 | P | 1,500 | $25.33 | Purchase +$37,995 | 35,659 | No | Form 4 |
| Semedo Anthony B. | Mar 5, 2025 | Mar 5, 2025 | P | 600 | $25.25 | Purchase +$15,150 | 600 | No | Form 4 |
| Berry Lance AExecutive VP, CFO | Feb 28, 2025 | Mar 4, 2025 | A | 34,435 | $0.00 | $0 | 110,240 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 28, 2025 | Mar 4, 2025 | A | 24,301 | $0.00 | $0 | 184,932 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 28, 2025 | Mar 4, 2025 | A | 23,416 | $0.00 | $0 | 173,215 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 28, 2025 | Mar 4, 2025 | A | 6,297 | $0.00 | $0 | 137,438 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 28, 2025 | Mar 4, 2025 | A | 98,524 | $0.00 | $0 | 762,406 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 28, 2025 | Mar 4, 2025 | A | 18,398 | $0.00 | $0 | 98,243 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 24, 2025 | Feb 26, 2025 | S | 2,299 | $27.31 | Sale −$62,786 | 82,233 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 24, 2025 | Feb 26, 2025 | S | 470 | $27.31 | Sale −$12,836 | 81,763 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 24, 2025 | Feb 26, 2025 | S | 672 | $27.31 | Sale −$18,352 | 81,091 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 24, 2025 | Feb 26, 2025 | S | 1,246 | $27.31 | Sale −$34,028 | 79,845 | No | Form 4 |
| Berry Lance AExecutive VP, CFO | Feb 24, 2025 | Feb 26, 2025 | S | 3,259 | $27.31 | Sale −$89,003 | 75,805 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 24, 2025 | Feb 26, 2025 | S | 2,846 | $27.31 | Sale −$77,724 | 164,242 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 24, 2025 | Feb 26, 2025 | S | 591 | $27.31 | Sale −$16,140 | 163,651 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 24, 2025 | Feb 26, 2025 | S | 985 | $27.31 | Sale −$26,900 | 162,666 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 24, 2025 | Feb 26, 2025 | S | 2,035 | $27.31 | Sale −$55,576 | 160,631 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 24, 2025 | Feb 26, 2025 | S | 2,385 | $27.31 | Sale −$65,134 | 152,749 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 24, 2025 | Feb 26, 2025 | S | 490 | $27.31 | Sale −$13,382 | 152,259 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 24, 2025 | Feb 26, 2025 | S | 810 | $27.31 | Sale −$22,121 | 151,449 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 24, 2025 | Feb 26, 2025 | S | 1,650 | $27.31 | Sale −$45,062 | 149,799 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 24, 2025 | Feb 26, 2025 | S | 16,664 | $27.31 | Sale −$455,094 | 689,374 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 24, 2025 | Feb 26, 2025 | S | 13,784 | $27.31 | Sale −$376,441 | 675,590 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 24, 2025 | Feb 26, 2025 | S | 6,812 | $27.31 | Sale −$186,036 | 668,778 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 24, 2025 | Feb 26, 2025 | S | 4,896 | $27.31 | Sale −$133,710 | 663,882 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 24, 2025 | Feb 26, 2025 | S | 1,706 | $27.31 | Sale −$46,591 | 132,758 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 24, 2025 | Feb 26, 2025 | S | 814 | $27.31 | Sale −$22,230 | 131,944 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 24, 2025 | Feb 26, 2025 | S | 318 | $27.31 | Sale −$8,685 | 131,626 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 24, 2025 | Feb 26, 2025 | S | 485 | $27.31 | Sale −$13,245 | 131,141 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 12, 2024 | Dec 13, 2024 | G | 1,100 | $0.00 | $0 | 134,464 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Dec 11, 2024 | Dec 12, 2024 | S | 4,035 | $30.25 | Sale −$122,059 | 157,897 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Dec 11, 2024 | Dec 12, 2024 | S | 4,035 | $30.00 | Sale −$121,050 | 153,862 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 6, 2024 | Dec 10, 20244/A | S | 4,425 | $29.05 | Sale −$128,546 | 135,564 | No | Form 4/A |
| Green Andrew MVP Regulatory | Dec 4, 2024 | Dec 4, 2024 | S | 7,618 | $30.00 | Sale −$228,540 | 33,503 | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Oct 1, 2024 | Oct 2, 2024 | M | 12,430 | $21.55 | $267,867 | 152,419 | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Oct 1, 2024 | Oct 2, 2024 | S | 12,430 | $26.18 | Sale −$325,417 | 139,989 | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Oct 1, 2024 | Oct 2, 2024 | M · derivative | 12,430 | $21.55 | $267,867 | not reported | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 26, 2024 | Aug 27, 2024 | S | 3,167 | $26.55 | Sale −$84,084 | 161,932 | No | Form 4 |
| Getz Matthew AVP, Human Resources | Aug 16, 2024 | Aug 19, 2024 | S | 6,858 | $25.31 | Sale −$173,576 | 36,678 | No | Form 4 |
| Getz Matthew AVP, Human Resources | Aug 16, 2024 | Aug 19, 2024 | S | 2,562 | $25.31 | Sale −$64,844 | 34,116 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Aug 15, 2024 | Aug 16, 2024 | S | 2,383 | $25.76 | Sale −$61,386 | 165,099 | No | Form 4 |
| Semedo Anthony B. | Aug 13, 2024 | Aug 15, 2024 | S | 9,709 | $24.99 | Sale −$242,628 | 34,159 | No | Form 4 |
| Hoff Elizabeth A | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 25,064 | No | Form 4 |
| Semedo Anthony B. | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 43,868 | No | Form 4 |
| Borgstrom Marna P | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 42,763 | No | Form 4 |
| Burbank Jeffrey H | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 47,471 | No | Form 4 |
| Bullock James | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 62,322 | No | Form 4 |
| Salveson Jon W | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 123,515 | No | Form 4 |
| Bevevino Daniel J | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 143,736 | No | Form 4 |
| Ackerman Thomas F | May 30, 2024 | Jun 3, 2024 | A | 6,289 | $0.00 | $0 | 143,571 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | May 10, 2024 | May 13, 2024 | S | 1,250 | $23.42 | Sale −$29,275 | 167,482 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | May 9, 2024 | May 10, 2024 | S | 979 | $23.79 | Sale −$23,290 | 168,732 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 20, 2024 | Mar 21, 2024 | S | 2,183 | $20.39 | Sale −$44,511 | 83,296 | No | Form 4 |
| Green Andrew MVP Regulatory | Mar 15, 2024 | Mar 18, 2024 | S | 1,462 | $20.00 | Sale −$29,240 | 41,121 | Yes | Form 4 |
| Green Andrew MVP Regulatory | Mar 14, 2024 | Mar 15, 2024 | S | 3,994 | $20.00 | Sale −$79,880 | 42,583 | Yes | Form 4 |
| Getz Matthew AVP, Human Resources | Mar 12, 2024 | Mar 14, 2024 | S | 5,000 | $19.94 | Sale −$99,700 | 43,536 | No | Form 4 |
| Mackin James PPresident & CEO | Mar 5, 2024 | Mar 14, 20244/A | S | 13,996 | $18.72 | Sale −$262,005 | 706,038 | No | Form 4/A |
| Davis John EChief Commercial Officer | Mar 5, 2024 | Mar 14, 20244/A | S | 2,022 | $18.72 | Sale −$37,852 | 165,690 | No | Form 4/A |
| Getz Matthew AVP, Human Resources | Mar 5, 2024 | Mar 14, 20244/A | S | 1,157 | $18.72 | Sale −$21,659 | 48,536 | No | Form 4/A |
| Green Andrew MVP Regulatory | Mar 5, 2024 | Mar 14, 20244/A | S | 1,160 | $18.72 | Sale −$21,715 | 46,577 | No | Form 4/A |
| Holloway Jean FSVP, General Counsel | Mar 5, 2024 | Mar 14, 20244/A | S | 2,380 | $18.72 | Sale −$44,554 | 169,711 | No | Form 4/A |
| Maney Rochelle L.VP, Quality | Mar 5, 2024 | Mar 14, 20244/A | S | 1,157 | $18.72 | Sale −$21,659 | 46,569 | No | Form 4/A |
| Horton AmyVP, Chief Accounting Officer | Mar 5, 2024 | Mar 14, 20244/A | S | 1,152 | $18.72 | Sale −$21,565 | 139,989 | No | Form 4/A |
| Mackin James PPresident & CEO | Mar 1, 2024 | Mar 14, 20244/A | A | 28,618 | $0.00 | $0 | 720,034 | No | Form 4/A |
| Davis John EChief Commercial Officer | Mar 1, 2024 | Mar 14, 20244/A | A | 5,724 | $0.00 | $0 | 167,712 | No | Form 4/A |
| Getz Matthew AVP, Human Resources | Mar 1, 2024 | Mar 14, 20244/A | A | 3,578 | $0.00 | $0 | 49,693 | No | Form 4/A |
| Green Andrew MVP Regulatory | Mar 1, 2024 | Mar 14, 20244/A | A | 3,578 | $0.00 | $0 | 47,737 | No | Form 4/A |
| Holloway Jean FSVP, General Counsel | Mar 1, 2024 | Mar 14, 20244/A | A | 5,724 | $0.00 | $0 | 172,091 | No | Form 4/A |
| Maney Rochelle L.VP, Quality | Mar 1, 2024 | Mar 14, 20244/A | A | 3,578 | $0.00 | $0 | 47,726 | No | Form 4/A |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 1, 2024 | Mar 14, 20244/A | A | 5,724 | $0.00 | $0 | 86,985 | No | Form 4/A |
| Stanton Marshall S.SVP, Clinical & MD Affair | Mar 1, 2024 | Mar 14, 20244/A | S | 1,506 | $18.72 | Sale −$28,192 | 85,479 | No | Form 4/A |
| Horton AmyVP, Chief Accounting Officer | Mar 1, 2024 | Mar 14, 20244/A | A | 3,578 | $0.00 | $0 | 141,141 | No | Form 4/A |
| Mackin James PPresident & CEO | Feb 27, 2024 | Mar 14, 20244/A | S | 4,837 | $19.83 | Sale −$95,918 | 691,416 | No | Form 4/A |
| Getz Matthew AVP, Human Resources | Feb 27, 2024 | Mar 14, 20244/A | S | 325 | $19.83 | Sale −$6,445 | 46,115 | No | Form 4/A |
| Holloway Jean FSVP, General Counsel | Feb 27, 2024 | Mar 14, 20244/A | S | 485 | $19.83 | Sale −$9,618 | 166,367 | No | Form 4/A |
| Davis John EChief Commercial Officer | Feb 27, 2024 | Mar 14, 20244/A | S | 584 | $19.83 | Sale −$11,581 | 161,988 | No | Form 4/A |
| Horton AmyVP, Chief Accounting Officer | Feb 27, 2024 | Mar 14, 20244/A | S | 325 | $19.83 | Sale −$6,445 | 137,563 | No | Form 4/A |
| Green Andrew MVP Regulatory | Feb 27, 2024 | Mar 14, 20244/A | S | 421 | $19.83 | Sale −$8,348 | 44,159 | No | Form 4/A |
| Maney Rochelle L.VP, Quality | Feb 27, 2024 | Mar 14, 20244/A | S | 370 | $19.83 | Sale −$7,337 | 44,148 | No | Form 4/A |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 27, 2024 | Mar 14, 20244/A | S | 465 | $19.83 | Sale −$9,221 | 81,261 | No | Form 4/A |
| Getz Matthew AVP, Human Resources | Feb 26, 2024 | Mar 14, 20244/A | S | 1,168 | $20.27 | Sale −$23,675 | 40,140 | No | Form 4/A |
| Getz Matthew AVP, Human Resources | Feb 26, 2024 | Mar 14, 20244/A | S | 1,112 | $20.27 | Sale −$22,540 | 46,440 | No | Form 4/A |
| Mackin James PPresident & CEO | Feb 26, 2024 | Mar 14, 20244/A | S | 17,868 | $20.27 | Sale −$362,184 | 650,573 | No | Form 4/A |
| Mackin James PPresident & CEO | Feb 26, 2024 | Mar 14, 20244/A | S | 12,968 | $20.27 | Sale −$262,861 | 696,253 | No | Form 4/A |
| Davis John EChief Commercial Officer | Feb 26, 2024 | Mar 14, 20244/A | S | 1,586 | $20.27 | Sale −$32,148 | 151,711 | No | Form 4/A |
| Davis John EChief Commercial Officer | Feb 26, 2024 | Mar 14, 20244/A | S | 1,875 | $20.27 | Sale −$38,006 | 162,572 | No | Form 4/A |
| Green Andrew MVP Regulatory | Feb 26, 2024 | Mar 14, 20244/A | S | 1,168 | $20.27 | Sale −$23,675 | 38,865 | No | Form 4/A |
| Green Andrew MVP Regulatory | Feb 26, 2024 | Mar 14, 20244/A | S | 1,199 | $20.27 | Sale −$24,304 | 44,580 | No | Form 4/A |
| Holloway Jean FSVP, General Counsel | Feb 26, 2024 | Mar 14, 20244/A | S | 1,295 | $20.27 | Sale −$26,250 | 155,559 | No | Form 4/A |
| Holloway Jean FSVP, General Counsel | Feb 26, 2024 | Mar 14, 20244/A | S | 1,543 | $20.27 | Sale −$31,277 | 166,852 | No | Form 4/A |
| Maney Rochelle L.VP, Quality | Feb 26, 2024 | Mar 14, 20244/A | S | 1,168 | $20.27 | Sale −$23,675 | 39,214 | No | Form 4/A |
| Maney Rochelle L.VP, Quality | Feb 26, 2024 | Mar 14, 20244/A | S | 1,114 | $20.27 | Sale −$22,581 | 44,518 | No | Form 4/A |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 26, 2024 | Mar 14, 20244/A | S | 1,576 | $20.27 | Sale −$31,946 | 72,513 | No | Form 4/A |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 26, 2024 | Mar 14, 20244/A | S | 1,431 | $20.27 | Sale −$29,006 | 81,726 | No | Form 4/A |
| Horton AmyVP, Chief Accounting Officer | Feb 26, 2024 | Mar 14, 20244/A | S | 1,168 | $20.27 | Sale −$23,675 | 132,436 | No | Form 4/A |
| Horton AmyVP, Chief Accounting Officer | Feb 26, 2024 | Mar 14, 20244/A | S | 966 | $20.27 | Sale −$19,581 | 137,888 | No | Form 4/A |
| Getz Matthew AVP, Human Resources | Feb 23, 2024 | Mar 14, 20244/A | A | 3,366 | $0.00 | $0 | 41,308 | No | Form 4/A |
| Getz Matthew AVP, Human Resources | Feb 23, 2024 | Mar 14, 20244/A | A | 7,412 | $0.00 | $0 | 47,552 | No | Form 4/A |
| Mackin James PPresident & CEO | Feb 23, 2024 | Mar 14, 20244/A | A | 40,404 | $0.00 | $0 | 668,441 | No | Form 4/A |
| Mackin James PPresident & CEO | Feb 23, 2024 | Mar 14, 20244/A | A | 58,648 | $0.00 | $0 | 709,221 | No | Form 4/A |
| Davis John EChief Commercial Officer | Feb 23, 2024 | Mar 14, 20244/A | A | 5,386 | $0.00 | $0 | 153,279 | No | Form 4/A |
| Davis John EChief Commercial Officer | Feb 23, 2024 | Mar 14, 20244/A | A | 12,736 | $0.00 | $0 | 164,447 | No | Form 4/A |
| Green Andrew MVP Regulatory | Feb 23, 2024 | Mar 14, 20244/A | A | 3,366 | $0.00 | $0 | 40,033 | No | Form 4/A |
| Green Andrew MVP Regulatory | Feb 23, 2024 | Mar 14, 20244/A | A | 6,914 | $0.00 | $0 | 45,779 | No | Form 4/A |
| Holloway Jean FSVP, General Counsel | Feb 23, 2024 | Mar 14, 20244/A | A | 5,386 | $0.00 | $0 | 156,854 | No | Form 4/A |
| Holloway Jean FSVP, General Counsel | Feb 23, 2024 | Mar 14, 20244/A | A | 12,836 | $0.00 | $0 | 168,395 | No | Form 4/A |
| Maney Rochelle L.VP, Quality | Feb 23, 2024 | Mar 14, 20244/A | A | 3,366 | $0.00 | $0 | 40,382 | No | Form 4/A |
| Maney Rochelle L.VP, Quality | Feb 23, 2024 | Mar 14, 20244/A | A | 6,418 | $0.00 | $0 | 45,632 | No | Form 4/A |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 23, 2024 | Mar 14, 20244/A | A | 5,386 | $0.00 | $0 | 74,089 | No | Form 4/A |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 23, 2024 | Mar 14, 20244/A | A | 10,644 | $0.00 | $0 | 83,157 | No | Form 4/A |
| Horton AmyVP, Chief Accounting Officer | Feb 23, 2024 | Mar 14, 20244/A | A | 3,366 | $0.00 | $0 | 133,604 | No | Form 4/A |
| Horton AmyVP, Chief Accounting Officer | Feb 23, 2024 | Mar 14, 20244/A | A | 6,418 | $0.00 | $0 | 138,854 | No | Form 4/A |
| Tyrs FlorianVP, Global Operations | Feb 27, 2024 | Feb 29, 2024 | S | 339 | $19.83 | Sale −$6,722 | 21,558 | No | Form 4 |
| Tyrs FlorianVP, Global Operations | Feb 26, 2024 | Feb 28, 2024 | S | 893 | $20.27 | Sale −$18,101 | 21,897 | No | Form 4 |
| Tyrs FlorianVP, Global Operations | Feb 23, 2024 | Feb 26, 2024 | A | 6,537 | $0.00 | $0 | 22,790 | No | Form 4 |
| Thomson Robert CVP Research & Development | Feb 23, 2024 | Feb 26, 2024 | A | 8,165 | $0.00 | $0 | 13,291 | No | Form 4 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Feb 23, 2024 | Feb 26, 2024 | A | 14,800 | $0.00 | $0 | 68,703 | No | Form 4 |
| Maney Rochelle L.VP, Quality | Feb 23, 2024 | Feb 26, 2024 | A | 7,893 | $0.00 | $0 | 37,016 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 23, 2024 | Feb 26, 2024 | A | 89,001 | $0.00 | $0 | 628,037 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 23, 2024 | Feb 26, 2024 | A | 7,893 | $0.00 | $0 | 130,238 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 23, 2024 | Feb 26, 2024 | A | 19,610 | $0.00 | $0 | 151,468 | No | Form 4 |
| Green Andrew MVP Regulatory | Feb 23, 2024 | Feb 26, 2024 | A | 11,100 | $0.00 | $0 | 36,667 | No | Form 4 |
| Getz Matthew AVP, Human Resources | Feb 23, 2024 | Feb 26, 2024 | A | 9,250 | $0.00 | $0 | 37,942 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 23, 2024 | Feb 26, 2024 | A | 19,734 | $0.00 | $0 | 147,911 | No | Form 4 |
| Berry Lance AExecutive VP, CFO | Feb 23, 2024 | Feb 26, 2024 | A | 37,000 | $0.00 | $0 | 79,064 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 20, 2024 | Feb 22, 2024 | M | 59,225 | $16.30 | $965,368 | 611,105 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 20, 2024 | Feb 22, 2024 | S | 59,225 | $18.85 | Sale −$1,116,391 | 551,880 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 20, 2024 | Feb 22, 2024 | S | 10,088 | $18.87 | Sale −$190,361 | 541,792 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 20, 2024 | Feb 22, 2024 | S | 2,756 | $18.87 | Sale −$52,006 | 539,036 | No | Form 4 |
| Mackin James PPresident & CEO | Feb 20, 2024 | Feb 22, 2024 | M · derivative | 59,225 | $16.30 | $965,368 | not reported | No | Form 4 |
| Tyrs FlorianVP, Global Operations | Feb 20, 2024 | Feb 22, 2024 | S | 249 | $18.87 | Sale −$4,699 | 16,253 | No | Form 4 |
| Getz Matthew AVP, Human Resources | Feb 20, 2024 | Feb 22, 2024 | S | 1,329 | $18.87 | Sale −$25,078 | 29,058 | No | Form 4 |
| Getz Matthew AVP, Human Resources | Feb 20, 2024 | Feb 22, 2024 | S | 366 | $18.87 | Sale −$6,906 | 28,692 | No | Form 4 |
| Maney Rochelle L.VP, Quality | Feb 20, 2024 | Feb 22, 2024 | S | 407 | $18.87 | Sale −$7,680 | 29,123 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 20, 2024 | Feb 22, 2024 | S | 2,060 | $18.87 | Sale −$38,872 | 128,673 | No | Form 4 |
| Davis John EChief Commercial Officer | Feb 20, 2024 | Feb 22, 2024 | S | 496 | $18.87 | Sale −$9,360 | 128,177 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 20, 2024 | Feb 22, 2024 | S | 1,329 | $18.87 | Sale −$25,078 | 122,711 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Feb 20, 2024 | Feb 22, 2024 | S | 366 | $18.87 | Sale −$6,906 | 122,345 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 20, 2024 | Feb 22, 2024 | S | 1,871 | $18.87 | Sale −$35,306 | 133,514 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 20, 2024 | Feb 22, 2024 | S | 464 | $18.87 | Sale −$8,756 | 133,050 | No | Form 4 |
| Holloway Jean FSVP, General Counsel | Feb 20, 2024 | Feb 22, 2024 | S | 1,192 | $18.87 | Sale −$22,493 | 131,858 | No | Form 4 |
| Davis John ESenior VP, Global Sales | Jan 2, 2024 | Jan 4, 2024 | M | 13,562 | $16.30 | $221,061 | 142,295 | Yes | Form 4 |
| Davis John ESenior VP, Global Sales | Jan 2, 2024 | Jan 4, 2024 | S | 13,562 | $18.00 | Sale −$244,116 | 128,733 | Yes | Form 4 |
| Davis John ESenior VP, Global Sales | Jan 2, 2024 | Jan 4, 2024 | M · derivative | 13,562 | $16.30 | $221,061 | not reported | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Jan 2, 2024 | Jan 4, 2024 | M | 21,229 | $16.30 | $346,033 | 154,749 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Jan 2, 2024 | Jan 4, 2024 | S | 21,229 | $18.00 | Sale −$382,122 | 133,520 | Yes | Form 4 |
| Holloway Jean FSVP, General Counsel | Jan 2, 2024 | Jan 4, 2024 | M · derivative | 21,229 | $16.30 | $346,033 | not reported | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 15, 2023 | Dec 19, 2023 | M | 14,397 | $16.30 | $234,671 | 138,437 | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 15, 2023 | Dec 19, 2023 | S | 14,397 | $19.00 | Sale −$273,543 | 124,040 | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 15, 2023 | Dec 19, 2023 | M · derivative | 14,397 | $16.30 | $234,671 | not reported | Yes | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Dec 6, 2023 | Dec 8, 2023 | A | 20,191 | $17.83 | $360,006 | 124,040 | No | Form 4 |
| Berry Lance AExecutive VP, CFO | Dec 6, 2023 | Dec 8, 2023 | A | 42,064 | $17.83 | $750,001 | 42,064 | No | Form 4 |
| Berry Lance AExecutive VP, CFO | Dec 6, 2023 | Dec 8, 2023 | A · derivative | 93,633 | $17.83 | $1,669,476 | 93,633 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Nov 27, 2023 | Nov 29, 2023 | S | 2,101 | $17.34 | Sale −$36,431 | 105,599 | No | Form 4 |
| Horton AmyVP, Chief Accounting Officer | Nov 27, 2023 | Nov 29, 2023 | G | 1,750 | $17.51 | $30,643 | 103,849 | No | Form 4 |